Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

被引：10
|
作者：
Suzuki, Hiroyuki [1 ]
Shimose, Shigeo [1 ]
Iwamoto, Hideki [1 ]
Niizeki, Takashi [1 ]
Kawaguchi, Takumi [1 ]
机构：
[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, 67 Asahi Machi, Kurume 8300011, Japan
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2024年 / 30卷 / 02期
关键词：
Fatty liver; Metabolic syndrome; Immunotherapy; Hepatocellular carcinoma;
D O I：
10.3350/cmh.2023.0557
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：262 / 265
页数：4
相关论文
共 19 条
  • [1] Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD
    Suzuki, Hiroyuki
    Tanaka, Toshimitsu
    Yamaguchi, Shotaro
    Miwa, Keisuke
    Kawaguchi, Takumi
    JOURNAL OF HEPATOLOGY, 2024, 80 (04) : e150 - e151
  • [2] Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
    Fukunaga, Shuhei
    Mukasa, Michita
    Nakano, Dan
    Tsutsumi, Tsubasa
    Kawaguchi, Takumi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01)
  • [3] Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
    Suzuki, Hiroyuki
    Tsutsumi, Tsubasa
    Kawaguchi, Machiko
    Amano, Keisuke
    Kawaguchi, Takumi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03)
  • [4] Changing from NAFLD to MASLD: Cumulative inci-dence of gallstones between patients with NAFLD and those with MASLD in Asia
    Fukunaga, Shuhei
    Nakane, Tomoyuki
    Mukasa, Michita
    Takedatsu, Hidetoshi
    Kawaguchi, Takumi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [5] From NAFLD to MASLD: Meta-analysis and systematic review of NAFLD patients in Turkiye in terms of metabolic profile and MASLD potential
    Akdas, Sevginur
    Yazihan, Nuray
    HEPATOLOGY FORUM, 2024, 5 (03): : 126 - 138
  • [6] No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC
    Copil, Francisca
    Campani, Claudia
    Lequoy, Marie
    Sultanik, Philippe
    Blaise, Lorraine
    Wagner, Mathilde
    Ganne-Carrie, Nathalie
    Ozenne, Violaine
    Nault, Jean Charles
    Thabut, Dominique
    Ratziu, Vlad
    Allaire, Manon
    JOURNAL OF HEPATOLOGY, 2024, 80 : S441 - S441
  • [7] No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC
    Copil, Francisca-Dora
    Campani, Claudia
    Lequoy, Marie
    Sultanik, Philippe
    Blaise, Lorraine
    Wagner, Mathilde
    Ganne-Carrie, Nathalie
    Ozenne, Violaine
    Thabut, Dominique
    Nault, Jean-Charles
    Ratziu, Vlad
    Allaire, Manon
    LIVER INTERNATIONAL, 2024, 44 (04) : 931 - 943
  • [8] Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort
    Perazzo, Hugo
    Pacheco, Antonio Guilherme
    Griep, Rosane Harter
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e72 - e74
  • [9] Changing from NAFLD to MASLD: The implications for health-related quality of life data
    Hashida, Ryuki
    Nakano, Dan
    Kawaguchi, Machiko
    Younossi, Zobair M.
    Kawaguchi, Takumi
    JOURNAL OF HEPATOLOGY, 2024, 80 (06) : e249 - e251
  • [10] NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options
    Vallianou, Natalia G.
    Kounatidis, Dimitris
    Psallida, Sotiria
    Vythoulkas-Biotis, Nikolaos
    Adamou, Andreas
    Zachariadou, Tatiana
    Kargioti, Sofia
    Karampela, Irene
    Dalamaga, Maria
    METABOLITES, 2024, 14 (07)
12